Endonovo Therapeutics Receives USPTO Notice of Allowance for Patent Covering 
Production of Biomolecules From Adult Stem Cells
Endonovo Adds Production of Biological Molecules From Adult Stem
Cells to Its Patent Licensing Program
LOS ANGELES, CA -- (Marketwired) -- 03/30/16 --  Endonovo
Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), an
innovative biotechnology company developing bioelectronics-based
products and therapies for regenerative medicine, announced today it
has received a Notice of Allowance from the U.S. Patent and Trademark
Office for a patent application entitled "Biological Molecules
Produced by Electromagnetically Stimulating Living Mammalian Cells."
The patent application covers the production of biological molecules,
including growth factors and cytokines in adult stem cells using the
Company's proprietary technologies. This Notice of Allowance
concludes substantive examination of the patent application and is
expected to result in the issuance of a U.S. patent in the near
The Company has added this technology to its patent licensing program
as it begins to pursue potential revenue producing applications of
its portfolio of intellectual property.
Endonovo Chairman and CEO, Alan Collier commented, "we are excited
about the issuance of this patent covering the production of
biological molecules from adult stem cells, which can be used to
produce human proteins." Conventional methods of protein production
include recombinant techniques used with bacteria or CHO cells.
According to Thomson Reuters, the biologics sector is set for an
unprecedented level of activity as U.S. companies have rapidly
increased their biologics development during the past five years. The
market for next-generation biologics is estimated to reach a value of
$30 billion by 2024, according to Visiongain. These next-generation
biologics will seek to address shortcomings in current therapies,
including inconvenient dosing and potential side-effects.
"Some applications from this technology include the production of
biomolecules for research purposes or the potential production of
next-generation biologics. "We are interested in potentially
licensing this technology or partnering with a larger
pharmaceutical/drug company to develop it," concluded Mr. Collier.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is an innovative biotechnology company
developing bioelectronic devices and therapies for regenerative
medicine. Endonovo's Immunotronics(TM) platform is a non-invasive,
non-implantable bioelectronic device for treating/preventing vital
organ failure through the reduction of inflammation, cell death and
the promotion of regeneration. Endonovo's Cytotronics(TM) platform
provides for a method of expanding and manipulating cells using
simulated microgravity and Time-Varying Electromagnetic Fields
(TVEMF) for tissue engineering and cell therapies. The Company's
initial concentration is on the treatment of acute and chronic
inflammatory conditions of the liver using its proprietary
Immunotronics(TM) platform.
Safe Harbor Statement
This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All statements, trends, analysis, and other information contained in
this press release including words such as "anticipate," "believe,"
"plan," "estimate," "expect," "intend," and other similar expressions
of opinion, constitute forward-looking statements. Any such
forward-looking statements involve risks and uncertainties that could
cause actual results to differ materially from any future results
described within the forward-looking statements. Risk factors that
could contribute to such differences include those matters more fully
disclosed in the Company's reports filed with the Securities and
Exchange Commission. The forward-looking information provided herein
represents the Company's estimates as of the date of the press
release, and subsequent events and developments may cause the
Company's estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future.
Therefore, this forward-looking information should not be relied upon
as representing the Company's estimates of its future financial
performance as of any date subsequent to the date of this press
Investors: Sign Up for Email Alerts on Endonovo
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Vice President of Investor Relations
(800) 701-1223, Ext. 108